Madrigal Pharmaceuticals
Yahoo Finance • 3 days ago
Noteworthy Tuesday Option Activity: WSBF, MDGL, NKE
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Waterstone Financial Inc (Symbol: WSBF), where a total volume of 724 contracts has been traded thus far today, a contract... Full story
Yahoo Finance • 5 days ago
Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus
Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story
Yahoo Finance • 14 days ago
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug
Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. shares increased following positive news about corporate earnings... Full story
Yahoo Finance • 20 days ago
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
Key Points RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW... Full story
Yahoo Finance • 20 days ago
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
RTW Investments disclosed a significant buy of Cogent Biosciences(NASDAQ:COGT) in its February 17, 2026, SEC filing, adding 4,124,755 shares in a trade estimated at $115.95 million based on quarterly average pricing. What happened Accord... Full story
Yahoo Finance • last month
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 20, Bank of America Securities lowered the price target on Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) f... Full story
Yahoo Finance • 2 months ago
MKKGY or MDGL: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Merck KGaA (MKKGY) or Madrigal (MDGL). But which of these two stocks presents investors with the better value opportunity right now? Let's take a clos... Full story
Yahoo Finance • 4 months ago
Here are the most and least likely M&A targets in biotech, according to Truist
[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story
Yahoo Finance • 4 months ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today an... Full story
Yahoo Finance • 4 months ago
2 Predictions for Novo Nordisk in 2026
Key Points Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo Nordisk's shares appear attrac... Full story
Yahoo Finance • 4 months ago
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
Key Points Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no shares of MBX at the end of t... Full story
Yahoo Finance • 4 months ago
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the third quarter, fueled by continued gains... Full story
Yahoo Finance • 5 months ago
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equities continue to rally in the third quarter, the period w... Full story
Yahoo Finance • 5 months ago
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: Jefferies Global Healthcare C... Full story
Yahoo Finance • 5 months ago
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality o... Full story
Yahoo Finance • 5 months ago
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index gaining 0.4% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 6 months ago
Notable Monday Option Activity: MDGL, MRK, BHVN
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Madrigal Pharmaceuticals Inc (Symbol: MDGL), where a total of 1,259 contracts have traded so far, representing approximately 125,9... Full story
Yahoo Finance • 6 months ago
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
Viking Therapeutics (NASDAQ:VKTX [https://seekingalpha.com/symbol/VKTX]) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t... Full story
Yahoo Finance • 6 months ago
Stocks of possible M&A targets have been crushing the market. Goldman says these 6 are the most likely to get bought.
Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story
Yahoo Finance • 6 months ago
Analysts See 11% Upside For JHML
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story
